| |
Significant pain at D6 post-surgery |
|
| |
No (n = 100) |
Yes (n = 28) |
P |
| Preoperative data |
Age, yrs, mean ± SD
BMI, kg/m2, mean ± SD
Men
ASA score ³ 3
Diabetes mellitus
Alcoholism
Smoking
Cardiac disease
Vascular disease
Depressive syndrome |
60.6 ± 8.3
25.8 ± 5.1
73 (73.0)
45 (45.0)
21 (21.0)
33 (33.0)
78 (78.0)
19 (19.0)
23 (23.0)
20 (20.0) |
60.6 ± 10.1
25.0 ± 4.6
18 (64.3)
7 (25.0)
6 (21.4)
7 (25.0)
24 (85.7)
2 (7.1)
6 (21.4)
7 (25.0) |
0.99
0.44
0.37
0.06
0.96
0.42
0.37
0.16
0.86
0.57 |
| Peroperative data |
Propofol dose, mg, median (IQR)
Remifentanil, mg, median (IQR)
Lidocaine mg, median (IQR)
Levobupivacaine dose, mg, median (IQR)
Operative time, min, median (IQR)
Muscle-sparing technique
Supra-lobar surgery |
1560 (831–2180)
1.95 (1.51–2.65)
118 (100–200)
42.1 (32.5–57.1)
211 (168–246)
45 (46.9)
57 (58.1)
|
1750 (1300–2060)
1.87 (1.52–2.32)
100 (50–175)
45.4 (33.7–58.2)
214 (186–245)
7 (26.9)
17 (65.3)
|
0.35
0.61
0.10
0.64
0.68
0.07
0.50
|
| Postoperative data |
Levobupivacaine daily dose, mg, median (IQR)
Numbers of days of TEA median (IQR)
Numbers of days of chest tube, median (IQR)
D1 NRS, median (IQR)
Total pulmonary complications
Atelectasis
Postoperative pneumonia |
170 (120–98)
6 (5–6)
5 (5–6)
0 (0–2)
25 (25.0)
14 (14.0)
13 (13.0) |
171 (125–218)
6 (5–6)
6 (5–6)
2 (0–3)
6 (21.4)
5 (17.9)
2 (7.1) |
0.74
0.25
0.51
0.02
0.69
0.56
0.52 |
